12866 related articles for article (PubMed ID: 10628361)
1. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice.
Kawamura I; Lacey E; Yamamoto N; Sakai F; Takeshita S; Inami M; Nishigaki F; Naoe Y; Tsujimoto S; Manda T; Shimomura K; Goto T
Anticancer Res; 1999; 19(5B):4105-11. PubMed ID: 10628361
[TBL] [Abstract][Full Text] [Related]
2. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI.
Kawamura I; Lacey E; Inami M; Nishigaki F; Naoe Y; Tsujimoto S; Manda T; Goto T
Anticancer Res; 1999; 19(5B):4091-7. PubMed ID: 10628359
[TBL] [Abstract][Full Text] [Related]
3. Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor.
Kawamura I; Yamamoto N; Sakai F; Yamazaki H; Naoe Y; Inami M; Manda T; Shimomura K
Anticancer Res; 1999; 19(1A):341-8. PubMed ID: 10226565
[TBL] [Abstract][Full Text] [Related]
4. Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice.
Kawamura I; Yamamoto N; Sakai F; Yamazaki H; Goto T
Anticancer Res; 1999; 19(5B):4099-103. PubMed ID: 10628360
[TBL] [Abstract][Full Text] [Related]
5. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice.
Tanaka K; Urata N; Mikami M; Ogasawara M; Matsunaga T; Terashima N; Suzuki H
Inflamm Res; 2007 Jan; 56(1):17-23. PubMed ID: 17334666
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model.
Kawamura I; Morishita R; Tomita N; Lacey E; Aketa M; Tsujimoto S; Manda T; Tomoi M; Kida I; Higaki J; Kaneda Y; Shimomura K; Ogihara T
Gene Ther; 1999 Jan; 6(1):91-7. PubMed ID: 10341880
[TBL] [Abstract][Full Text] [Related]
7. Effect of FR143430, a novel cytokine suppressive agent, on adenocarcinoma colon26-induced cachexia in mice.
Yamamoto N; Kawamura I; Nishigaki F; Tsujimoto S; Naoe Y; Inami M; Elizabeth L; Manda T; Shimomura K
Anticancer Res; 1998; 18(1A):139-44. PubMed ID: 9568068
[TBL] [Abstract][Full Text] [Related]
8. [Role of NF-kappa B in cancer cachexia].
Zhou W; Jiang ZW; Jiang J; Li N; Li JS
Zhonghua Wai Ke Za Zhi; 2004 Jun; 42(11):683-6. PubMed ID: 15329260
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
[TBL] [Abstract][Full Text] [Related]
10. In vivo gene transfer of murine interleukin-4 inhibits colon-26-mediated cancer cachexia in mice.
Sturlan S; Beinhauer BG; Oberhuber G; Huang L; Aasen AO; Rogy MA
Anticancer Res; 2002; 22(5):2547-54. PubMed ID: 12529962
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice.
Yasumoto K; Mukaida N; Harada A; Kuno K; Akiyama M; Nakashima E; Fujioka N; Mai M; Kasahara T; Fujimoto-Ouchi K
Cancer Res; 1995 Feb; 55(4):921-7. PubMed ID: 7850809
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine.
Kanzaki M; Soda K; Gin PT; Kai T; Konishi F; Kawakami M
Cytokine; 2005 Dec; 32(5):234-9. PubMed ID: 16338141
[TBL] [Abstract][Full Text] [Related]
13. Anti-cachectic effect of FK317, a novel anti-cancer agent, in colon26 and LX-1 models in mice.
Naoe Y; Kawamura I; Inami M; Matsumoto S; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
Jpn J Cancer Res; 1998 Dec; 89(12):1318-25. PubMed ID: 10081493
[TBL] [Abstract][Full Text] [Related]
14. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.
Strassmann G; Fong M; Freter CE; Windsor S; D'Alessandro F; Nordan RP
J Clin Invest; 1993 Nov; 92(5):2152-9. PubMed ID: 8227330
[TBL] [Abstract][Full Text] [Related]
15. Conjugated linoleic acid preserves gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma.
Graves E; Hitt A; Pariza MW; Cook ME; McCarthy DO
Res Nurs Health; 2005 Feb; 28(1):48-55. PubMed ID: 15625711
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival of tumor-bearing rats with repetitive low-dose recombinant tumor necrosis factor.
Sheppard BC; Venzon D; Fraker DL; Langstein HN; Jensen JC; Norton JA
Cancer Res; 1990 Jul; 50(13):3928-33. PubMed ID: 2354441
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a cancer cachectic factor.
Todorov P; Cariuk P; McDevitt T; Coles B; Fearon K; Tisdale M
Nature; 1996 Feb; 379(6567):739-42. PubMed ID: 8602222
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with GH, insulin, and indomethacin alleviates cancer cachexia in a mouse model.
Chen SZ; Qiu ZG
J Endocrinol; 2011 Feb; 208(2):131-6. PubMed ID: 21106721
[TBL] [Abstract][Full Text] [Related]
19. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
Joppa MA; Gogas KR; Foster AC; Markison S
Peptides; 2007 Mar; 28(3):636-42. PubMed ID: 17204351
[TBL] [Abstract][Full Text] [Related]
20. Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma.
McCarthy DO; Whitney P; Hitt A; Al-Majid S
Res Nurs Health; 2004 Jun; 27(3):174-84. PubMed ID: 15141370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
